## **Provider Order Form**

## **KRYSTEXXA (PEGLOTICASE)**



PATIENT	
Full Name:	DOB:
Mobile Phone:	
Allergies:	NKDA
Patient status: New to therapy Continuing therapy Last Treatme	nt Date: Next Treatment Date:
DIAGNOSIS ICD-10 code (must be specified)	
☐ Chronic Gout M1A ☐ Other:	
PROVIDER	
Provider Name: Provider NPI	:
Practice Name: Referral Coor	dinator Name:
Practice Address:	
Phone: Fax: En	nail:
PRE-MEDICATION	
☐ Acetaminophen (Tylenol) PO ☐ 500 mg ☐ Diphenhydramine (Benadryl) ☐ PO ☐ IV ☐ 25 mg ☐ Methylprednisolone (Solu-Medrol) IV ☐ 40 mg ☐ Cetrizine (Zyrtec) 10 mg PO ☐ Other:	☐ 650 mg ☐ 1000 mg ☐ 50 mg ☐ 125 mg
THERAPY ADMINISTRATION	
MedicationDose⊠ Krystexxa(Pegloticase), IV□ 8 mgin 250ml 0.9% sodium chloride	Frequency ☐ Every 2 weeks
Patient will be on methotrexate or other immunomodulation therapy.  **Product information suggests co-administration of 15 mg weekly of methotrexate and folic acid therapy if not contraindicated. If co-administering methotrexate, start weekly methotrexate and folic acid or folinic acid supplementation at least 4 weeks prior to initiation, and throughout treatment with Krystexxa.**	
Refills ☐ Zero ☐ 12 months ☐ Order valid for 1 year unless otherwise stated ☐ Infuse over 120 minutes. ☐ Flush with 0.9% sodium chloride at infusion completion. ☐ Provide nursing care per Uptiv Health Nursing Procedures, including reaction management and post-procedure observation.	
LABORATORY ORDERS	
☐ CBC ☐ at each dose ☐ CMP ☐ at each dose ☐ CRP ☐ at each dose ☐ URIC ACID PRIOR TO EACH INFUSION ☐ Other	every   every   every
SPECIAL INSTRUCTIONS	
PLEASE ATTACH THE FOLLOWING SO WE CAN MOST EFFICIENT	TLY PROCESS THE PATIENT'S ORDER
☐ Patient Demographics ☐ Insurance card ☐ Progress Notes supporting DY☐ Baseline Serum Uric Acid level	Glucose-6-phosphate dehydrogenase (G6PD)
Provider Signature	Date
<b>UPTIVHEALTH.COM Phone</b> : (734) 203-0176 <b>Fax</b> : (88	B8) 373-5528 Email: referral@uptivhealth.com